These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 12510249)

  • 1. Treatment of arteriosclerosis.
    Schmermund A; Erbel R
    Dtsch Med Wochenschr; 2003 Jan; 128(1-2):41-7. PubMed ID: 12510249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J
    Clin Ther; 2006 Jun; 28(6):832-48. PubMed ID: 16860167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of metabolic syndrome.
    Wagh A; Stone NJ
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years.
    Robinson JG; Maheshwari N
    Am J Cardiol; 2005 Feb; 95(3):373-8. PubMed ID: 15670547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
    Blinc A; Poredos P
    Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
    Fisher M; Folland E
    Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome.
    Chang SM; Yazbek N; Lakkis NM
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):193-7. PubMed ID: 15170709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.